Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV000488231 | SCV000574758 | likely benign | not provided | 2023-11-01 | criteria provided, single submitter | clinical testing | SZT2: BP4, BS2 |
Ambry Genetics | RCV002313745 | SCV000849364 | benign | Inborn genetic diseases | 2024-02-29 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Labcorp Genetics |
RCV000488231 | SCV001000891 | benign | not provided | 2024-01-27 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000488231 | SCV001770602 | likely benign | not provided | 2020-12-09 | criteria provided, single submitter | clinical testing | |
Genome Diagnostics Laboratory, |
RCV000488231 | SCV001932609 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000488231 | SCV001964215 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Prevention |
RCV003905033 | SCV004724439 | likely benign | SZT2-related disorder | 2022-08-25 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |